Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

BACKGROUND: Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction...

全面介紹

Na minha lista:
書目詳細資料
發表在:BMC Cancer
Main Authors: Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof, Goldschmidt, Hartmut
格式: Artigo
語言:Inglês
出版: BioMed Central 2019
主題:
Study Protocol
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6537200/
https://ncbi.nlm.nih.gov/pubmed/31138244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5600-x
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍